In a preclinical study using mouse xenograft models with NIS-expressing thyroid cancer, we confirmed the high accumulation of [211At]NaAt in K1-NIS tumors, showing better dose-dependent antitumor effects than [131I]NaI (Watabe et al. 2019, 2022). The gene discussed is SLC5A5; the disease is thyroid gland carcinoma.